The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs. Symptoms of ...

Patients with atopic dermatitis (AD) who received ruxolitinib cream experienced a rapid, clinically meaningful, and sustained improvement in their itch. Patients with atopic dermatitis (AD) who ...

Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...

Johnson & Johnson announced it will pay $1.25 billion to buy an experimental bispecific antibody targeting atopic dermatitis (AD) from Numab Therapeutics. The all-cash deal, which was announced ...

Please provide your email address to receive an email when new articles are posted on . Pediatric patients with atopic dermatitis who were treated with dupilumab and topical corticosteroids ...

– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 Results showed that patients with AD treated ...

"Galderma’s Nemluvio shows itch reduction in 48 hours" was originally created and published by Clinical Trials Arena, a ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...

In patients with moderate to severe atopic dermatitis (AD), abrocitinib, an oral JAK inhibitor, relieved itch more quickly than the monoclonal antibody dupilumab (Dupixent), in a multicenter ...

A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new study says.